Phase II trial: ETH47-201
This is an early-stage clinical trial, called ETH47-201, currently in what's known as 'Phase II'. At this stage, trials often look at how safe a new treatment might be and how well it works. However, specific details about what health problems this trial is looking at, what treatments it's testing, and who can and cannot join are not yet openly shared. This is a temporary measure, approved by the Health Research Authority (HRA). The HRA has given permission for the full study details to be kept private for now, but they will be made public within 30 months after the trial has concluded. This means that at the moment, we don't have enough information to explain the study's purpose or requirements in more detail. We will update this information as soon as it becomes available.
At a glance
What is this study about?
This information describes a Phase II clinical trial known as ETH47-201. Clinical trials are research studies that test new treatments, such as medicines, or new ways of using existing treatments, to see if they are safe and effective for people. Phase II trials are an intermediate step in this process. They typically involve a larger group of people than earlier Phase I trials and are designed to collect more information about the treatment's safety and how well it works, often for a specific health condition.
However, for this particular trial, ETH47-201, the full details about what health problems it is looking into, what treatments are being tested, and who can take part are not yet public. The Health Research Authority (HRA), which oversees health research in the UK, has given permission for this information to be held back for a period. This practice, known as deferral of publication, sometimes happens to protect intellectual property or for other research-related reasons. While this means we can't provide specific details right now, it's important to know that the HRA's approval means they have reviewed this decision.
The good news is that this deferral is temporary. All the comprehensive details about the trial, including its specific aims, the interventions being studied, and the full eligibility criteria, will be made public. This will happen within 30 months after the trial has officially concluded. Once that information is released, we will update our records to provide a complete picture of what this study is all about.
Key takeaways
- This is a Phase II clinical trial, ETH47-201.
- Full study details are temporarily not public, as approved by the HRA.
- All specific information will be released within 30 months after the trial ends.
- Currently, we know it accepts 'any age' and 'all sexes'.
- Patient.info will update this page as more information becomes available.
Who may be eligible?
Currently, we don't have the specific details about who can or cannot take part in this study, ETH47-201. This information includes things like specific health conditions, other medicines someone might be taking, or their general health.
The Health Research Authority (HRA) has approved a temporary delay in sharing these specific details. This is not unusual in some research studies. The full rules for joining or not joining the study will be made public within 30 months after the trial finishes.
When this information becomes available, we will be able to tell you more about the specific health requirements, age limits (beyond just 'any age'), and any other particular conditions that would make someone suitable or unsuitable for this trial.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am interested in joining a clinical trial.
- I understand that full trial details are not yet available.
- I am happy to wait for more information about who can join.
- I am aware that this trial accepts participants of 'any age' and 'all sexes'.
What does participation involve?
At this time, because the full details of this trial (ETH47-201) are not yet public, we cannot accurately describe what taking part would involve. Usually, participation in a clinical trial might include regular visits to a clinic or hospital, different types of assessments (like blood tests, scans, or questionnaires), taking a new medication or treatment regularly, and follow-up appointments after the main treatment period ends. The total length of time someone would be involved in a trial also varies greatly.
However, for this specific study, the Health Research Authority (HRA) has deferred the publication of these details. This means we don't currently know the specifics about: * **Visits:** How many, how often, and what they would involve. * **Assessments:** What medical tests or checks would be carried out. * **Medication/Treatment:** What is being given, how often, and for how long. * **Follow-up:** What check-ups are needed after the main treatment phase. * **Total Duration:** How long a participant would be involved in the study from start to finish.
We will update this section with a clear explanation of what participation involves as soon as the full study details are released by the Health Research Authority (HRA), which will be within 30 months after the trial ends.
Potential risks and benefits
Locations (2)
- Imperial College Respiratory Research UnitCity onlyLondon, England
- Medicines Evaluation Unit LimitedCity onlyManchester, England
Common questions
What is a Phase II trial?
Phase II trials are an important step where researchers test a new treatment or medicine on a larger group of people. The main goals are usually to see how safe it is and if it shows signs of working for a specific health issue.
Why aren't all the details public yet?
The Health Research Authority (HRA) has given permission for the researchers to delay publishing the full details for a period of time. This can happen for different reasons, but all information will eventually be made public.
When will I be able to see the full study information?
The Health Research Authority (HRA) has stated that all the complete details about the trial will be added to the study record within 30 months after the trial has ended. We will update our information then.
Can anyone join this trial?
At the moment, we don't have the specific rules about who can or cannot join. The available information just says 'any age' and 'all sexes'. We'll know more once the full details are released.
Who is the Health Research Authority (HRA)?
The HRA is a UK organisation that protects the interests of patients and the public in health research. They review and approve research studies to make sure they are ethical and well-planned.
How to find out more
Tika Endeladze
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.